CD274 and neoplasm: PD-1/PD-L1 axis inhibitors exert their antitumor effects by alleviating PD-L1-mediated inhibition of tumor-infiltrating T lymphocytes and enhancing the proliferation of tumor-infiltrating T-regulatory cells (Treg) [23, 24].